VERA - Vera Therapeutics Inc
Vera Therapeutics Inc Logo

VERA - Vera Therapeutics Inc

https://veratx.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Allogene Therapeutics ( NASDAQ:ALLO ) , AvalonBay Communities ( NYSE:AVB )
Benzinga • 1 month, 1 week ago • score: 0.40
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Brian Cheng downgraded the rating for Allogene Therapeutics, Inc.
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases in the United States. The company is headquartered in South San Francisco, California.

52W High
$51.61
52W Low
$18.53
MA Status:
50D: Above 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.16
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-3.60
EV/Revenue (<3 favorable)
N/A
P/S (TTM) (<3 favorable)
N/A
P/B (<3 favorable)
3.30
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
3.96%
Institutions (25–75% balanced)
109.94%
Shares Outstanding
63,824,000
Float
42,918,900
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
0
EPS (TTM)
-3.59
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.55%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
0.8549
Previous
0.9146
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025